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Antiviral activitycellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) is an important
binding receptor for dengue virus (DENV) that recognizes N-glycosylation sites on the viral E-glycoprotein.
DENV cannot bind nor infect the human B-cell line Raji/0. However, DENV productively infects Raji/DC-SIGN
+ cells that constitutively express DC-SIGN on their surface. IL-4-treated monocytes, expressing high levels of
DC-SIGN, are also susceptible for DENV infection. Several carbohydrate-binding agents (CBAs), such as the
plant lectins HHA, GNA (mannose-speciﬁc) and UDA (N-acetylglucosamine-speciﬁc), inhibited dose-
dependently the binding of DENV and subsequently viral replication in Raji/DC-SIGN+ cells (EC50: 0.1–
2.2 μM). These CBAs were clearly more active against DENV in IL-4-treated monocytes (EC50: 4–56 nM).
However, the CBAs were devoid of antiviral activity in DENV-susceptible Vero-B (DC-SIGN−) cells,
demonstrating cell type-dependent differences in viral entry mechanisms.
© 2009 Elsevier Inc. All rights reserved.IntroductionDengue virus (DENV) is a single-stranded positive RNA virus of the
Flaviviridae family that is transmitted by the Aedes aegyptimosquito in
tropical and subtropical countries. Four genetically related DENV
serotypes are known. Theworld health organization (WHO) estimates
that 2.5 billion people are at risk to get infected with dengue. Every
year there are 50 up to 100 million cases of DENV infections and
approximately half a million patients require hospitalization. DENV
infection can generate ﬂu-like symptoms that can progress to dengue
hemorrhagic fever/dengue shock syndrome (DHF/DSS) which is
characterized by vascular leakage and thrombocytopenia causing
25,000 deaths each year (Halstead, 2007; Mairuhu et al., 2004).
Dengue viruses expand their range due to the increasing habitat of the
mosquito and international travel. Vaccine development would be
imperative because dengue virus infections form an important
economic burden especially in the developing countries. The only
way at this moment to prevent DENV infection is eradication of the
mosquito. The development of a dengue virus vaccine is difﬁcult,
because every serotype can cause DHF/DSS during a secondary
infection. One serotype provides life-long immunity, but infection
with a heterologous virus enhances the disease severity. This
phenomenon is called antibody-dependent enhancement (ADE) and
occurs often in children born to dengue-immune mothers. A
tetravalent vaccine with low reactogenicity would be effective.
Recently, a mouse and a Rhesus monkey model is proven to be
effective to test antiviral compounds and possible vaccines (Bente(D. Schols).
ll rights reserved.et al., 2005; Blaney et al., 2005; Schul et al., 2007), however further
investigation is required.
During a blood meal, the infected mosquito injects the virus in the
skin where dendritic cells (DC) are the ﬁrst target for DENV. Several
investigators reported that DC-speciﬁc intercellular adhesion mole-
cule 3-grabbing non-integrin (DC-SIGN) is essential in the infection
and transmission process (Lozach et al., 2005; Navarro-Sanchez et al.,
2003; Tassaneetrithep et al., 2003). DC-SIGN, mainly expressed on DC
and alveolar macrophages, is a C-type (calcium-dependent) trans-
membrane receptor composed of four domains: a cytoplasmic
domain, a transmembrane domain, seven to eight extracellular neck
repeats and a carbohydrate recognition domain (CRD) (Geijtenbeek
et al., 2000c; Mitchell et al., 2001; Soilleux et al., 2002). Recently, it has
been shown that monocytes, but not T or B cells, are the principal
target cells for DENV infection in human peripheral blood mono-
nuclear cells (Kou et al., 2008). DC-SIGN has the capability to bind
different pathogens, like human immunodeﬁciency virus (HIV)
(Geijtenbeek et al., 2000b), human cytomegalovirus (HCMV) (Halary
et al., 2002), hepatitis C virus (HCV) (Lai et al., 2006), Mycobacterium
tuberculosis and several parasites and yeasts (van Kooyk and
Geijtenbeek, 2003). By interaction of the virus with DC-SIGN, the
virus hijacks the DC function to modulate the immune system and to
disseminate the virus to the secondary lymphoid organs. Ligand
interaction is abrogated with mannan and EGTA, indicating that
recognition of carbohydrate structures by the lectin domain of DC-
SIGN is involved (Geijtenbeek et al., 2000b, 2000a; Pöhlmann et al.,
2001). The CRD recognizes speciﬁc carbohydrate structures like high-
mannose N-glycans present on the HIV gp120 envelope (Curtis et al.,
1992). DC-SIGN may be an important target for antiviral drugs
because it plays an instrumental role during infection. Agents that
Fig. 1. Dose dependent DENV infection in Raji/DC-SIGN+ cells 4 days post infection. The
cells were incubated with medium alone as control (- - -) or with different
concentrations of DENV (gray histogram) at 37 °C for 4 days. The upper panel shows
the infectivity with 1000 PFU/ml, the middle panel 200 PFU/ml and in the lower panel
40 PFU/ml. The viral activity was quantiﬁed by ﬂowcytometry using 5 μg/ml anti-DENV
type 2 antibody clone 3H5 (left) or 5 μl/ml anti-ﬂavivirus antibody clone 4G2 (right).
(MFI=Mean Fluorescence of Intensity).
Fig. 2. Time dependent DENV infection in Raji/DC-SIGN+ cells. The cells were incubated
with medium alone as control (- - -) or with DENV (1000 PFU/ml) (gray histogram) at
37 °C and then evaluated at day 0, at day 2, at day 3 and at day 4. Viral infection was
quantiﬁed by ﬂow cytometry using 5 μg/ml anti-DENV type 2 antibody clone 3H5.
(MFI=Mean Fluorescence of Intensity).
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the entry process of the virus. Indeed, carbohydrate-binding agents
(CBAs) have been shown to prevent capture of HIV, simian
immunodeﬁciency virus (SIV) and HCV to DC-SIGN+ cells and prevent
transmission of HIV to CD4+ cells in vitro (Balzarini et al., 2007;
Balzarini, 2007; François et al., 2008; Turville et al., 2005). The DENV
E-protein, with two potential N-linked glycosylation sites, is the only
glycoprotein on the surface of DENV and is responsible for the
interaction with DC-SIGN (Lozach et al., 2005).
Here, we evaluated the effect of CBAs on DENV infection using DC-
SIGN-transfected Raji cells. These cells can efﬁciently and productively
be infected with DENV. The CBAs efﬁciently prevented DC-SIGN-
mediated infection in Raji/DC-SIGN+ cells. When freshly-isolated
monocytes were treated with IL-4 to enhance the expression of DC-
SIGN, they also become sensitive to DENV and the CBAs showed
potent antiviral activity. The CBAs inhibited the adsorption step of
DENV to the cells andwe assume that CBAs interact with the E-protein
of DENV as this protein has two potential N-linked glycosylation sites.
The CBAs used in our study do not show agglutination of human
erythrocytes (Balzarini et al., 2004a) and they do not require uptake
by the cells to induce antiviral activity. Together with the low toxicity
of these CBAs and their high stability (Balzarini et al., 2004a) they
should be considered as potential anti-DENV agents to be further
explored in in vivo models.
Results
Optimization of dengue virus infection in Raji/DC-SIGN+ cells
Previously, Gentry et al. (1982) prepared a large panel of
monoclonal antibodies (mAbs) directed against the four DENV
serotypes and they proved valuable for diagnostic purposes (Gentry
et al., 1982; Henchal et al., 1982). Out of 22 different clones, clone 3H5
was the most speciﬁc antibody to neutralize DENV type 2 NGC at hightiter. Clone 4G2 recognizes all DENV serotypes and is also used to
detect DENV infection (Mondotte et al., 2007). We compared the two
mAb clones in DENV-infected Raji/DC-SIGN+ cells using different
amounts of virus input. After 4 h incubation with the virus, the cells
were washed and analyzed by ﬂow cytometry 4 days post infection
(Fig. 1). Flow cytometry data indicated that mAb 3H5 gives a higher
MFI to detect dengue virus production in comparison to mAb 4G2.
1000 PFU/ml DENV represented the best (highest) infection dose and
was used in the next set of experiments. Higher amounts of DENV
input resulted in a saturation of the ﬂuorescence signal and thus the
number of DENV-infected cells (data not shown). To determine the
time course of DENV infection, Raji/DC-SIGN+ cells were collected
and analyzed by ﬂow cytometry for viral antigen expression at several
days post infection (Fig. 2). In our hands, viral infection was at an
optimal level to be detected by ﬂow cytometry at day 4 post infection.
These results were consistent with our other data, where DENV
infection was quantiﬁed by RT-PCR reaching a maximum at 4 days
post infection (data not shown).
DC-SIGN expression makes cells sensitive for DENV
To investigate the importance of DC-SIGN in the infection of DENV,
we compared DC-SIGN+-transfected Raji cells to the wild-type Raji/0
cells. Parental Raji cells were not susceptible to DENV infection. This is
in contrast to the DC-SIGN+ cells which were able to become
productively infected by DENV. The MFI signal representing the
DENV infection was increased from 1.6±2.5 MFI for Raji/0 cells
(background) to 49.4±5.0 MFI for Raji/DC-SIGN+ cells (Fig. 3A).
Preincubating Raji/DC-SIGN+ cells with a speciﬁc anti-DC-SIGN mAb
(mAb 120612) before the infection with DENV, resulted in inhibition
of viral RNA production by 88%±4%. In contrast, IgG control isotype
matched mAb showed no inhibitory effect (Fig. 3B). This is in
accordance with the results of Tassaneetrithep et al. (2003). We
then investigated the effect of mannan on the interaction between
Raji/DC-SIGN+ cells and DENV. We found that 2 mg/ml mannan
strongly reduced the interaction of DENVwith Raji/DC-SIGN+ cells by
82±4.4% (Fig. 3C). It is noteworthy that the EC50 for mannan is 8.2±
5.2 μg/ml (Table 1). The astroglioma U87 wild-type cells were not
sensitive to DENV infection, whereas the stably transfected U87/DC-
SIGN+ cells were highly sensitive to DENV infection (data not shown).
In addition, primary immature monocytes, which are DC-SIGN−, are
Fig. 3. DENV infectivity is DC-SIGN dependent. (A) Raji/0 (DC-SIGN−) cells were incubated with medium alone as control (- - -) or infected with DENV (1000 PFU/ml) (gray
histogram) and Raji/DC-SIGN+ cells were infectedwith DENV (1000 PFU/ml) (\) at 37 °C and evaluated 4 days post infection. Viral infectionwas quantiﬁed by ﬂow cytometry using
5 μg/ml anti-DENV type 2 antibody. (B) Raji/DC-SIGN+ cells were preincubated with 20 μg/ml anti-DC-SIGN antibody or IgG control isotype matched antibody for 30 min at room
temperature. After the preincubation period, DENV (1000 PFU/ml) was added to the cells. After 4 days, supernatant was collected and RNA was extracted according to the
manufacturer's protocol. The percentage of viral replication was measured by RT-PCR and is shown in the presence or absence of anti-DC-SIGN antibody or IgG control isotype
matched antibody. (C) Raji/DC-SIGN+ cells were incubated with medium alone as control (- - -) or infected with DENV (1000 PFU/ml)) (\) at 37 °C (left). 2 mg/ml mannan was
added simultaneously with DENV to Raji/DC-SIGN+ cells (gray histogram) (right) and the cells were analyzed for DENV antigen after 4 days by ﬂow cytometry using 5 μg/ml anti-
DENV type 2 antibody clone 3H5. The data are from one representative experiment which was conﬁrmed in ﬁve independent experiments. (MFI=Mean Fluorescence of Intensity).
69M.M.F. Alen et al. / Virology 387 (2009) 67–75not sensitive to DENV. After a differentiation process, induced by IL-4,
these IL-4-treated monocytes express high levels of DC-SIGN and
become susceptible to DENV infection (monocytes: CD14 expres-
sion=98%±1%;DC-SIGNexpression=0.3%±0.1%; IL-4-treatedmono-
cytes: CD14 expression=30%±12%; DC-SIGN expression=79%±6%).
These observations lend further support to the critical role of DC-SIGN
during DENV infection. Indeed, all these results indicate an important
role for DC-SIGN as an entry receptor for DENV and the interaction
betweenDC-SIGNandDENV is likelydependentonmannose-containing
N-glycans present on the DENV envelope.
Inhibitory effect of HHA, GNA, UDA and polyanions in Raji/DC-SIGN+ cell
cultures infected with DENV
Based on the potential of CBAs to recognize glycans present on the
viral envelope, it would be interesting to investigate the antiviralTable 1
Overview of the antiviral activity against DENV of several different classes of compounds ev
Test compound Raji/DC-SIGN+ cells
EC50a EC50b CC50c
Flow cytometry RT-PCR
HHA (nM) 110±40 210±80 N5,000
GNA (nM) 210±110 410±390 N5,000
UDA (nM) 2200±1300 1830±970 N20,000
DS (MW N500,000) (μg/ml) 4.4±1.4 7.1±0.6 N100
DS (MW 5000) (μg/ml) N100 N100 N100
Mannan (μg/ml) 8.2±5.2 9.1±3.8 N2000
(ND=not determined, DS=dextran sulphate).
a 50% effective concentration, or drug concentration required to inhibit DENV infections in
cells. Values are mean±standard deviation of 2 to 3 separate experiments.
b 50% effective concentration, or drug concentration required to inhibit DENV infections in
PCR in the supernatants. Values are mean±standard deviation of 2 to 3 separate experime
c 50% cell cytotoxic concentration, or drug concentration required to cause 50% cell deathpotential of the CBAs against DENV infection. Raji/DC-SIGN+ cells
were incubated with different concentrations of the lectins HHA, GNA
or UDA together with the virus for 4 h and the cells were harvested
4 days post infection. Expression of viral proteins on the cells was
quantiﬁed by ﬂow cytometry using the anti-E protein antibody, clone
3H5 (Fig. 4). HHA, GNA and UDA had the capability to dose-
dependently inhibit DENV infection. HHA and GNA were the most
potent CBAs with an EC50 of 110±40 nM and 210±110 nM,
respectively. UDA was 10- to 20-fold less effective (EC50: 2200±
1300 nM) (Table 1). The drug concentration required to cause 50% cell
death (CC50) was not obtained and is higher than the highest
concentration tested.
We also evaluated several highly sulphated polyanions on DENV
infection in Raji/DC-SIGN+ cells. Cells were infected with DENV and
different amounts of low and highmolecular weight (LWand HW) DS.
The cultures were analyzed 4 days later for DENV infection by ﬂowaluated in Raji/DC-SIGN+ cells, VERO-B cells and IL-4-treated monocytes
VERO cells IL-4-treated monocytes
EC50a EC50b CC50c EC50b CC50c
Flow cytometry RT-PCR RT-PCR
N5,000 N5,000 N5,000 4.4±1.2 N5,000
N5,000 N5,000 N5,000 3.2±1 N5,000
N20,000 N20,000 N20,000 56±50 N20,000
N100 N100 N100 ND ND
N100 N100 N100 ND ND
N2000 N2000 N2000 ND ND
Raji/DC-SIGN+ cells and Vero-B cells and for 50%measured by antigen expression on the
Raji/DC-SIGN+ cells, Vero-B cells and IL-4-treated monocytes for 50% measured by RT-
nts.
in Raji/DC-SIGN+ cells, Vero-B cells and IL-4-treated monocytes.
Fig. 4. Dose dependent inhibitory effect of HHA, GNA and UDA in DENV infected Raji/DC-SIGN+ cells. Cells were incubated with medium alone (- - -) or with DENV (1000 PFU/ml)
(\) at 37 °C for 4 days. At the start of the infection 250,100, 20, 4, 0.8, 0.16 μg/ml HHA (50 kDa) or GNA (50 kDa) or UDA (8.7 kDa) was added to the cells. The effect of the compounds
(gray histogram) is compared with the virus control (\). Viral infectivity was quantiﬁed by ﬂow cytometry using 5 μg/ml anti-DENV type 2 antibody clone 3H5. (MFI=Mean
Fluorescence of Intensity.) The data shown are from one representative experiment, which was repeated three times with comparable results.
70 M.M.F. Alen et al. / Virology 387 (2009) 67–75cytometry. DS HW, but not DS LW, has the capability to inhibit DENV
infection in Raji/DC-SIGN+ cells by 90±7.5% at a concentration of
100 μg/ml (Fig. 5).The inhibitory effect of HHA, GNA, UDA and DS HW on DENV
infection was further studied by quantifying the production of DENV
particles in the supernatant of Raji/DC-SIGN+ cells measured by RT-
Fig. 6. Dose dependent effect of HHA, GNA and UDA in DENV infected Raji/DC-SIGN+
cells 4 days post infection measured by RT-PCR. Cells were infected with DENV
(1000 PFU/ml) at 37 °C and HHA, GNA, UDA or DS HW (100, 20, 4, 0.8 μg/ml) were
added at the start of the infection. After 4 days, supernatant was collected and RNAwas
extracted. The absolute total amount of viral RNA was measured by RT-PCR. Mean % of
inhibition of the virus control±standard deviation of three independent experiments
are shown.
71M.M.F. Alen et al. / Virology 387 (2009) 67–75PCR (Table 1, second column). The compounds inhibited dose-
dependently DENV infection, although none of the compounds was
able to achieve 100% inhibition at the highest concentrations tested
(i.e. 100 μg/ml) (Fig. 6).
To determine whether DENV infection of Raji/DC-SIGN+ cells
produced also infectious virus, we performed a plaque assay in Vero-B
cells using DENV-infected Raji/DC-SIGN+ supernatants. The Vero-B
cell line is commonly used for DENV infections, because DENV induces
a cytopathic effect (CPE) on Vero-B cells whichmakes infection visible
and allows quantiﬁcation of the virus titer (von Sydow et al., 2000). In
contrast, Raji/DC-SIGN+ cells do not show CPE after DENV infection.
Raji/DC-SIGN+ cells were infected in the presence or absence of
various CBAs and after 4 h the cells were washed to remove virus and
compounds. The cells were incubated for 4 days and supernatants
were evaluated for infectious virus on amonolayer of Vero-B cells. The
data showed that the DC-SIGN+ cells produced infectious virus,
indicated by the formation of plaques in Vero-B cells. The plaque
formationwas reduced when the initial infection had been performed
in the presence of HHA, UDA, GNA or mannan (Fig. 7). Preincubation
of Raji/DC-SIGN+ cells with anti-DC-SIGN antibody (10 μg/ml)
reduced the production of infectious DENV by 42% (data not shown).
Effects of CBAs and polyanions in DENV-infected Vero-B cells and
potential other attachment factors for DENV
The activity of the compounds in DENV-infected Raji/DC-SIGN+
cells and Vero-B cells was compared. Vero-B cells were incubated with
virus and compounds for 4 h. After removing the excessive amount of
virus, the cells were incubated for 7 days and analyzed by intracellular
ﬂow cytometry. The compounds HHA, GNA, UDA and mannan had no
inhibitory activity in Vero-B cell cultures, suggesting a carbohydrate-
independent binding and infection process of DENV in Vero-B cells.
Surprisingly, also DS HW was not active against DENV in Vero-B cells
(Fig. 8).Fig. 5. Dose dependent inhibitory effect of DS HW and the effect of DS LW in DENV
infected Raji/DC-SIGN+ cells. (A) Cells were incubated with medium alone (- - -) or
with DENV (1000 PFU/ml) (\) at 37 °C for 4 days. At the start of the infection 100, 20
and 4 μg/ml DS HW was added to the cells. The effect of DS HW (dark histogram) is
compared with the virus control (\). The effect of 100 μg/ml DS LW (20 μM) is shown
in the light histogram. Viral infectivity was quantiﬁed by ﬂow cytometry using 5 μg/ml
anti-DENV type 2 antibody clone 3H5. (MFI=Mean Fluorescence of Intensity).Raji/DC-SIGN+ and Vero-B cells strongly express the CXCR4
receptor (Balzarini et al., 2007). To study whether this receptor may
be involved in the DENV infection process, we studied whether the
potent CXCR4 antagonist AMD3100 prevents infection of these cells
withDENV. Byﬂowcytometryanalysiswe foundno antiviral activity of
AMD3100 (up to 60 μg/ml) on DENV infection in Raji/DC-SIGN+ and
Vero-B cell cultures (data not shown). Also whereas the transfected
U87/DC-SIGN+ cell line appeared highly sensitive to DENV infection,
neither wild-type U87 cells nor U87/CD4+ and U87/CD4+/CXCR4+
cells were infectablewith DENV, indicating that thewell-knownHIV-1
(co)-receptors are not suitable receptors for DENV (data not shown).
Effect of CBAs in IL-4-treated monocytes infected with DENV
To determine the effect of CBAs in primary cells, we isolated
monocytes from PBMCs because it has been shown that monocytes
are the principal target cells for DENV infection in human PBMCs (Kou
et al., 2008). After a 5 day incubation period with IL-4, 78.5%±6% of
the monocytes express DC-SIGN. We then infected the IL-4-treated
cells with DENV in the presence or absence of CBAs. The lectins HHA,
GNA and UDA showed potent antiviral activity with EC50 of 4.4 nM for
HHA, 3.2 nM for GNA and 56 nM for UDA (Table 1). The compounds
showed no cytotoxic effects at the highest dose tested as determined
by light microscopic evaluation as no altered morphology of the
monocyte cultures was observed (5 μM for HHA and GNA and 20 μM
UDA) (Table 1).
Discussion
At the site of DENV exposure, the human skin, are different
subpopulations of DC that are believed to be the ﬁrst target during a
DENV infection. Indeed, Wu et al. (2000) demonstrated that epithelial
DC of a volunteer, vaccinated with an attenuated tetravalent vaccine,
stained positive for DENV glycoprotein by immunohistochemistry.
DC-SIGN is a DC-speciﬁc marker that recognizes high-mannose
glycans present on different pathogens. ICAM-2 and ICAM-3 are
cellular ligands for DC-SIGN. Interaction of DC-SIGN with ICAM-2
results in transendothelial migration of DC (Geijtenbeek et al., 2000a)
to the secondary lymphoid organs, where DC-SIGN binds ICAM-3 and
initiates activation of T-cells (Geijtenbeek et al., 2000c). DC-SIGN-
expressing DC are able to capture a variety of pathogens. After
degradation of the pathogen, DC present the antigens to T-cells in the
secondary lymphoid organs thereby activating the immune system.
Thus, the ﬁrst important target during an infection is DC-SIGN.
Geijtenbeek et al. (2000b) demonstrated that DC-SIGN binds HIV-1
Fig. 7. Raji/DC-SIGN+ cells produce infectious DENV. Raji/DC-SIGN+ cells were infected with DENV (1000 PFU/ml) at 37 °C in the presence or absence of compounds. After 4 days,
supernatant was collected and transmitted to a monolayer of Vero-B cells in different dilutions. (Right) Plaque assay of dilution 10−1 is shown: supernatant Raji/DC-SIGN+ cell
control (A), virus control (B), 100 μg/ml GNA (2 μM) (C), 100 μg/ml HHA (2 μM) (D), 2 mg/ml mannan (E) and 100 μg/ml UDA (11.5 μM) (F). (Left) PFU/ml is determined in the
supernatant of two independent experiments and shown as percentage cytopathic effect (% CPE) of the virus control±standard deviation.
Fig. 8. Effect of HHA, GNA, DS HW and mannan in DENV infected VERO cells. Cells were
incubated with medium alone (- - -) or with DENV (1000 PFU/ml) (\) at 37 °C for
7 days. During the infection 100 μg/ml HHA (2 μM), 100 μg/ml GNA (2 μM), 100 μg/ml
DS HW and 2 mg/ml mannan was added to the cells. The effect of the products (gray
histogram) is compared with the virus control (\). Cells were stained for intracellular
protein E production and quantiﬁed by ﬂow cytometry using 5 μg/ml anti-DENV type 2
antibody clone 3H5. (MFI=Mean Fluorescence of Intensity).
72 M.M.F. Alen et al. / Virology 387 (2009) 67–75envelope glycoprotein gp120 and enhances trans-infection of T-cells.
Other pathogens recognized by DC-SIGN are HCMV (Halary et al.,
2002), HCV (Lai et al., 2006), Mycobacterium tuberculosis and several
parasites and yeasts (van Kooyk and Geijtenbeek, 2003). The crystal
structure of DC-SIGN supports the high-mannose selectivity of the
receptor (Feinberg et al., 2001; Guo et al., 2004). HIV-1 envelope
glycoprotein gp120 contains an average of 18 to 30 N-glycans. In
contrast, DENV E-protein contains only 2 N-glycans (Asn-67 and Asn-
153). Asn-67 is thought to be unique for DENV among ﬂaviviruses and
it has recently been shown that Asn-67 is responsible for the
interaction of the DENV envelope with the DC-SIGN recognition
domain (Mondotte et al., 2007; Pokidysheva et al., 2006).
Carbohydrate-binding agents (CBAs) and polyanions have been
shown to qualify as potential microbicides to prevent HIV transmis-
sion by blocking virus entry (Balzarini and Van Damme, 2007;
Pollicita et al., 2008). Other enveloped viruses including SIV
(François et al., 2008), HCV (Bertaux et al., 2007) and HCMV
(Balzarini et al., 1991, 1992) are found to be inhibited by several
CBAs. In this study we used the DC-SIGN+ Raji cell line and IL-4-
treated monocytes as well as the DC-SIGN− Vero-B cell line to
evaluate the potential anti-DENV activity of a number of CBAs and
the polyanion dextran sulphate. To measure DENV infection we used
a DENV serotype 2 speciﬁc antibody, clone 3H5, because this clone
recognizes a speciﬁc sequence in the E-protein of DENV type 2 and
neutralizes the attachment of the virus (Hiramatsu et al., 1996).
HHA, GNA and UDA were shown to inhibit DENV infection in Raji/
DC-SIGN+ cells with an EC50 around 110–2200 nM. Although the
potency of these CBAs to inhibit DENV infection is less pronounced
than their antiviral activity against HIV (EC50: 6–140 nM in T cell
lines) and HCV infections (EC50: 3–180 nM) (Balzarini et al., 2004a;
Bertaux et al., 2007), the CBAs still proved to be very efﬁcient and
non-toxic at concentrations up to N5 μM to the Raji/DC-SIGN+ cells.
The antiviral activity of HHA, GNA and UDA against DENV is much
better in monocytes (EC50: 3–56 nM) and is comparable to HIV
infection in T cell lines and also to HIV infection in monocytes (EC50:
38–200 nM) (Pollicita et al., 2008). In addition, a much higher dose
of DENV was used to achieve a detectable infection in IL-4-treated
monocytes compared to Raji/DC-SIGN+ cells. This low efﬁciency of
infection can be due to a lower expression of DC-SIGN compared to
Raji/DC-SIGN+ cells, but also to the characteristics (e.g. non-dividing
cells) and heterogenicity of the monocyte population. The various
CBAs inhibited the capture of DENV to DC-SIGN, as measured by
their effect on the expression of viral antigens, and subsequently
prevented the production of new virions in the supernatant. Long-
term cell cultures of HIV with the mannose-speciﬁc CBAs, HHA or
GNA, select for mutated viruses by deleting the N-glycans in HIV-1
gp120. This in turn makes the virus sensitive to neutralizing
antibodies (Balzarini et al., 2004b, 2005). If CBAs induce this kind
of mutations in the DENV envelope on the N-glycosylation sites,these sites may become a target for immune cell attack. Production
of antibodies recognizing the N-glycosylation sites could result in
neutralization of all four DENV serotypes, either rendering the host
immune to heterologous DENV infections, or resulting in ADE and
ultimately making disease severity worse. This makes it necessary to
investigate the effect of CBAs in chronic DENV-2 infections as well as
in infections with other serotypes of DENV.
We found that the CBAs had no inhibitory activity against DENV
infections in Vero-B cells, most likely indicating that the entry of the
virus into Vero-B cells is independent of the carbohydrate-binding
interaction. Screening potential antiviral agents against DENV in Vero-
B cells should be questioned due to the lack of important attachment
factors like DC-SIGN and the lack of knowledge on the entry process of
DENV in Vero-B cells. The precise mechanism of the antiviral action of
CBAs in Raji/DC-SIGN+ cells is not completely elucidated. Preincuba-
tion of HIV with CBAs prior to the exposure to CD4+ cells, improved
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difference in antiviral activity of the CBAs when the CBAs were
preincubated with DENV prior to exposure to Raji/DC-SIGN+ cells
(data not shown). This may be due to a lower afﬁnity of the CBAs for
the envelope glycans of DENV than for HIV gp120, and thus a less tight
binding of the CBAs to the DENV glycans. So thenwe performed DENV
infection of Raji/DC-SIGN+ cells in the absence or presence of
compounds at 4 °C, and this allows no internalization of the virus
into the target cell. After an incubation period of 1 h, the cells were
thoroughly washed and further cultured at 37 °C (in the absence of
compounds) and 4 days later analyzed for DENV infection. The CBAs
were as active and thus able to inhibit the absorption of DENV to DC-
SIGN. This is in accordance with our HIV and HCV data and
interactions with DC-SIGN as also in these cell cultures CBAs inhibit
the binding of HIV and HCV to Raji/DC-SIGN+ cells (Balzarini et al.,
2005, Bertaux et al., 2007).
We excluded the role of the CXCR4 receptor during DENV infection,
because the CXCR4 receptor antagonist AMD3100 had no inhibitory
effect on infection in the Raji/DC-SIGN+ and Vero-B cell cultures,
which have constitutive CXCR4 expression (Balzarini et al., 2007). To
test whether CD4 could be an attachment receptor for DENV, we used
U87/CD4+ cells. Although U87/DC-SIGN+ cells are highly sensitive
for DENV infection, U87, U87/CD4+ and U87/CD4+/CXCR4+ cells are
not susceptible to DENV infection, indicating that also CD4 is not an
attachment receptor for DENV. This is in accordance with the
observation that monocytes, expressing DC-SIGN after a differentia-
tion process, are the principal targets of DENV and not the low level of
CD4 expression observed in monocytes (Kou et al., 2008).
Polyanions inhibit syncytia formation of CD4+ T-lymphocytes
induced by laboratory adapted HIV-1 strains. In sharp contrast,
polyanions do not have such an inhibitory activity against HIV-1
transmission from DC-SIGN+ cells to T-lymphocytes (Balzarini et al.,
2007). Here, we also did not observe an antiviral activity of the
polyanions (i.e. DS LW) against DENV infection of Raji/DC-SIGN+ cells
at 100 μg/ml. However, DS HW could block DENV infection in Raji/DC-
SIGN+ cells. The molecular mechanism behind this observation is
unclear, but it correlates with the observation that DS HWhas a higher
antiviral activity against HIV-1 than does DS LW (Busso and Resnick,
1990).
In conclusion, we set up an in vitro assay using DC-SIGN+ Raji cells
that are sensitive to DENV infection in order to evaluate potential
antiviral compounds. Our data highlights the importance of DC-SIGN
expression in order to make cells sensitive to DENV infection.
However, the DC-SIGN-dependent infection could not be inhibited
completely by a speciﬁc anti-DC-SIGN antibody and also not
completely by the CBAs, suggesting still other potential entry path-
ways of DENV in these cells. We also demonstrated the speciﬁcity of
CBAs to recognize carbohydrate binding sites on the virus envelope
and, therefore, interrupting the attachment of DENV (and HIV) to DC-
SIGN+ cells. While most compounds have their effect on a step in the
replication cycle of the virus inside the cell, the CBAs exhibit a unique
mechanism of antiviral action by inhibiting the virus entry process
through carbohydrate binding. This study provides the ﬁrst evidence
that CBAs have antiviral activity against DENV.
Materials and methods
Cells and viruses
All cell cultures were maintained at 37 °C in a humidiﬁed, CO2-
controlled atmosphere. African green monkey kidney cells (Vero-B
cells; ATCC CCL-81) were grown in Minimum Eagle's Medium
(MEM) (Invitrogen, Merelbeke, Belgium) supplemented with 10%
fetal bovine serum (FBS) (Hyclone, Perbio Science, Aalst, Belgium),
2 mM L-glutamine and 0.075% sodium bicarbonate (Invitrogen).
Wild-type Raji/0 and Raji/DC-SIGN+ cells were kindly provided byDr. L. Burleigh (Pasteur Institute, Paris, France). Raji/DC-SIGN+ cells
were constructed by Geijtenbeek et al. (2000b). These cell lines were
cultivated in RPMI-1640 medium supplemented with 10% FBS and
2 mM L-glutamine. Human astroglioma U87 wild-type cells and U87
cells expressing CD4 (U87/CD4+) were a kind gift from Dr. Dan R.
Littman (Skirball Institute of Biomolecular Medicine, New York, NY,
USA). U87/CD4+ cells were transfected with CXCR4 as described
previously (Hatse et al., 2001). U87 cells were transfected with a DC-
SIGN plasmid, a kind gift from Dr. Stefan Pöhlmann (Institute for
clinical and molecular virology, Erlangen, Germany) (Pöhlmann et
al., 2001), using FuGENE® 6 Transfection Reagent (Roche Molecular
Biochemicals, Mannheim, Germany) according to the manufacturer's
instructions. U87 cells were cultured in Dulbecco's modiﬁed Eagle's
medium (DMEM, Invitrogen) containing 10% FBS and 0.01 M HEPES
buffer. If U87 cells express CD4, 0.2 μg/ml geneticin (G-418 sulfate)
(Invitrogen) was added, if DC-SIGN is expressed, 50 μg/ml zeocin
(Invitrogen) was added and if CXCR4 is expressed, 1 μg/ml
puromycin (Sigma-Aldrich, St. Louis, MO, USA) was added to the
culture medium.
Dengue virus (DENV) serotype 2 New Guinea C (NGC) strain was
kindly provided by Prof. Dr. V. Deubel (Institut Pasteur, Lyon, France)
and propagated in Vero-B cells. Supernatant containing virus was
harvested at different time points post infection and stored at−80 °C.
Isolation and differentiation of monocytes
Buffy coat preparations from healthy donors were obtained from
the Blood Bank in Leuven, Belgium. Human peripheral blood mono-
nuclear cells (PBMCs) were ﬁrst isolated by density gradient
centrifugation over Lymphoprep (Nycomed, Oslo, Norway). Mono-
cytes were puriﬁed from PBMCs by a 2 h adherence step at 37 °C in
0.1% gelatin coated petridishes in culture RPMI medium. Nonadherent
cells were removed by extensive washing with medium and the
remaining adherent cells (monocytes) are collected. Monocytes were
grown in RPMI culture medium supplemented with 25 ng/ml IL-4
(R&D Systems, Abingdon, United Kingdom). After 5 days the
monocytes were differentiated, because CD14 expression decreases
dramatically whereas DC-SIGN expression was strongly upregulated,
as analyzed by ﬂow cytometry (our own data, Miller et al., 2008; Wu
et al., 2002).
Test compounds
The mannose-speciﬁc plant lectins from Hippeastrum hybrid
(HHA) (50 kDa), Galanthus nivalis (GNA) (50 kDa) and the N-
acetylglucosamine-speciﬁc plant lectin from Urtica dioica (UDA)
(8.7 kDa) were derived and puriﬁed from these plants as described
previously (Van Damme et al., 1987, 1988, 1991). Mannan, isolated
from Saccharomyces cerevisiae, and dextran sulphate (DS), (low
molecular weight 5 kDa and high molecular weight N500 kDa)
derived from Leuconostoc mesenteroides, were purchased from Sigma
(St. Louis, MO). The bicyclam AMD3100 was obtained from Anormed
(Langley, Canada). Puriﬁed DC-SIGN antibody was purchased from
R&D Systems (clone 120612,) and puriﬁed mouse IgG isotype control
antibody was purchased from BD Pharmingen (clone MOPC-173, BD
Biosciences, San Jose, CA).
Antiviral assays
Raji/0, Raji/DC-SIGN+, Vero-B cells and the U87 cell lines (0.5 106
cells/well) were infected with DENV (40, 200, 1000 PFU/ml) in the
absence or presence of compound for 4 h at 37 °C. IL-4-treated
monocytes (0.1106 cells/ml) were infected with a high multiplicity of
infection (MOI) of DENV in the absence or presence of compound for
4 h at 37 °C and analyzed for DENV infection after different time-
points. The cells werewashed twicewithmedium to remove excessive
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DC-SIGN+ cells were analyzed for DENV infection on day 0, 2, 3 and 4
after infection. U87 cell lines were incubated for 6 days and Vero-B
cells were incubated for 7 days.
The supernatant was always stored at −80 °C for RNA-extraction
and RT-PCR and the cells were used to detect DENV antigen by ﬂow
cytometry.
At the end of the culture period, the 50% cell cytotoxicity
concentration (CC50) was determined in IL-4-treated monocytes and
Vero-B cells by light microscopic evaluation for morphological
changes and for Raji/DC-SIGN+ cells by counting the cells in a Coulter
Counter (Analis, Ghent, Belgium).
RNA extraction and real time (RT)-PCR
Total RNA was extracted from 150 μl cell culture supernatant
using the Nucleospin RNA Virus Kit according to the manufacturer's
instructions (Macherey-Nagel, Düren, Germany). The sequences of
the forward (5′-TCGGAGCCGGAGTTTACAAA-3′ position 4628–4647)
and reverse (5′-TCTTAACGTCCGCCATGAT-3′, position 4722–4741)
Taqman primers were selected from non-structural gene 3 (NS3)
of DENV NGC using Primer Express software (version 2.0, Applied
Biosystems, Lennik, Belgium). The probe was selected between the
primers and is ﬂuorescently labeled with 6-carboxyﬂuorescein
(FAM) at the 5′ end as the reporter dye and with a quencher at
the 3′ end. The quencher is a minor groove binder (MGB) (5′-FAM-
ATTCCACACAATGTGGCA-MGB-3′, position 4656–4674). The nucleo-
tide sequence and position of the primers and probes were obtained
from the nucleotide sequence of DENV 2 NGC (Genbank accession
no. M29095) (Irie et al., 1989). One step RT-PCR was performed in a
25 μl reaction mixture containing 12.5 μl One-Step Reverse
Transcriptase qPCR Master Mix (Eurogentec, Seraing, Belgium),
900 nM forward primer, 900 nM reverse primer, 200 nM probe
and 100 ng sample RNA. RT-PCR was performed under the following
conditions: reverse transcription at 48 °C for 30 min, initial
denaturation at 95 °C for 10 min, followed by 40 cycles of
denaturation at 95 °C for 15 s, annealing and extension at 60 °C
for 1 min. RT-PCR was performed using the ABI 7500 Fast Real-Time
PCR System (Applied Biosystems, Branchburg, New Jersey, USA) and
data were analyzed with ABI PRISM 7500 SDS software (version
1.3.1, Applied Biosystems). Standard curves were made of dengue
virus plasmid with known concentrations to calculate the absolute
quantiﬁcation of infection.
Flow cytometry analysis
Raji/0 and Raji/DC-SIGN+ cells were infected with DENV and
incubated for 0, 2, 3 or 4 days. Cells were collected, washed with
phosphate buffered saline (PBS) supplemented with 2% FBS and
stainedwithmonoclonal anti-dengue virus type 2 antibody, speciﬁc to
the E-glycoprotein of DENV type 2 NGC (clone 3H5, Chemicon
International/Millipore, Billerica, MA) or with anti-ﬂavivirus group
antigen monoclonal antibody (clone 4G2, Chemicon International/
Millipore, Billerica, MA) (Henchal et al., 1982; Hiramatsu et al., 1996).
After an incubation period of 30 min at room temperature, cells were
washed with PBS and incubated with secondary phycoerythrin-
conjugated goat F(ab')2 anti-mouse antibody (1 μg/ml, Invitrogen)
for 30 min. Finally the cells were washed with PBS and ﬁxed with 1%
paraformaldehyde. Vero-B cells were infected with DENV and after
trypsin digestion, the cells were ﬁxed with 2% paraformaldehyde for
10min at 37 °C and then permeabilized with 90%methanol for 30 min
on ice. After washing the cells with PBS and 2% FBS the permeabilized
cells were stained with anti-dengue virus type 2 mAb (clone 3H5) for
30 min at room temperature. Then the cells were washed with PBS
and secondary phycoerythrin-conjugated goat F(ab')2 anti-mouse
antibody was added (Caltag Invitrogen, Carlsbad, CA).As a control for unspeciﬁc background staining, Raji/0, Raji/
DC-SIGN+ and Vero-B cells were stained in parallel with secondary
antibody only. Then the stained cells were washed and analyzed by
ﬂow cytometry with a FACSCalibur (BD, San Jose, CA). Data were
acquired and analyzed with CellQuest software (BD). The mean
ﬂuorescence of intensity (MFI) of the background staining was
subtracted from the MFI of each sample to obtain the percentage of
DENV-infected cells.
Viral plaque assay
Three 10-fold serial dilutions (10−1–10−3) were made for each
supernatant sample into 6-well plates containing a conﬂuent
monolayer of Vero-B cells. Following an incubation of 2 h, the cells
were washed 3 times with culture medium and overlaid with a
solution containing 0.5% Avicel® (Matrosovich et al., 2006) and
medium, supplemented with 2% FBS, 2 mM L-glutamine and 0.075%
sodium bicarbonate, in a ratio 1:1. Avicel restricts the spread of virus in
cell culture. After 1 week the cells were washed with PBS, ﬁxed with
70% ethanol and stained with 1% methylene blue solution to visualize
the plaques. Plaques were counted to determine the number of plaque
forming units per milliliter supernatant (PFU/ml).
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